-
My Account
My Account
BSE Live
Mar 04, 16:00Prev. Close
880.80
Open Price
871.50
Bid Price (Qty.)
874.50 (1)
Offer Price (Qty.)
874.50 (18)
NSE Live
Mar 04, 15:59Prev. Close
880.50
Open Price
874.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
874.90 (5)
| Quarterly Results of Aurobindo Pharma (in Rs. Cr.) | Dec '20 | Sep '20 | Jun '20 | Mar '20 | Dec '19 | |
| Net Sales/Income from operations | 3,701.14 | 4,425.43 | 3,337.25 | 3,534.28 | 3,258.10 | |
| Other Operating Income | 9.72 | 98.91 | 82.45 | 86.04 | 87.57 | |
| Total Income From Operations | 3,710.86 | 4,524.34 | 3,419.70 | 3,620.32 | 3,345.67 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,750.70 | 1,833.20 | 1,791.43 | 1,792.76 | 1,753.23 | |
| Purchase of Traded Goods | 3.48 | 2.45 | 5.14 | 0.68 | 1.11 | |
| Increase/Decrease in Stocks | -97.45 | 361.51 | -380.86 | -126.92 | -64.90 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 431.08 | 426.62 | 424.69 | 424.94 | 384.91 | |
| depreciat | 120.63 | 120.14 | 119.79 | 118.85 | 118.55 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 649.30 | 693.42 | 614.47 | 680.27 | 620.14 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 853.12 | 1,087.00 | 845.04 | 729.74 | 532.63 | |
| Other Income | 164.97 | 48.62 | 125.58 | 160.61 | 37.98 | |
| P/L Before Int., Excpt. Items & Tax | 1,018.09 | 1,135.62 | 970.62 | 890.35 | 570.61 | |
| Interest | 5.84 | 6.42 | 10.43 | 17.46 | 21.31 | |
| P/L Before Exceptional Items & Tax | 1,012.25 | 1,129.20 | 960.19 | 872.89 | 549.30 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 1,012.25 | 1,129.20 | 960.19 | 872.89 | 549.30 | |
| Tax | 271.74 | 327.66 | 245.51 | 147.85 | 130.23 | |
| P/L After Tax from Ordinary Activities | 740.51 | 801.54 | 714.68 | 725.04 | 419.07 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 740.51 | 801.54 | 714.68 | 725.04 | 419.07 | |
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 12.64 | 13.68 | 12.20 | 12.37 | 7.15 | |
| Diluted EPS | 12.64 | 13.68 | 12.20 | 12.37 | 7.15 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 12.64 | 13.68 | 12.20 | 12.37 | 7.15 | |
| Diluted EPS. | 12.64 | 13.68 | 12.20 | 12.37 | 7.15 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
11.02.2021
Aurobindo Pharm Standalone December 2020 Net Sales at Rs 3,710.86 crore, up 10.92% Y-o-Y
11.02.2021
Aurobindo Pharm Consolidated December 2020 Net Sales at Rs 6,364.91 crore, up 7.97% Y-o-Y
10.02.2021
Aurobindo Pharma Q3 net profit zooms over 4-fold to Rs 2,946.32 crore
11.11.2020
Aurobindo Pharma Q2 profit jumps 26% to Rs 805.6 crore; US business grows 12.5%
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL
